26 Jun 2017 | 12:56 AM
Research Report
Daily

Equity Research Report: Religare Morning Digest

The way markets have closed, we might see further profit taking on Wednesday, but our positive bias won’t change till Nifty holds above 7350.
16 Mar 2016 | 07:00 AM

    Religare Morning Digest – Highlights for today
 
Market Outlook for the day -The way markets have closed, we might see further profit taking on Wednesday, but our positive bias won’t change till Nifty holds above 7350.
Key Indices – Levels to watch out for the day
INDEX (Spot) RESISTANCE 2 RESISTANCE 1 LTP SUPPORT 1 SUPPORT 2
SENSEX 24830 24700 24551.17 24380 24200
NIFTY 7550 7500 7460.60 7400 7350
NIFTYBANK 15620 15450 15326.80 15150 14950
NIFTYIT 11000 10870 10730.45 10600 10480
News -
  • Lupin tumbled 7.59% at Rs 1,726.60 after the company clarified that the United States Food and Drug Administration inspected its Goa facility last week and cited 9 observations.
  • PGHH fell 0.99% to Rs 6,067.85 after the government prohibited manufacturing, selling and distributing fixed dose combination drugs with immediate effect.
  • Crompton Greaves lost 71.68% to Rs 43.90 following the demerger of consumer business. The scheme of arrangement in the nature of demerger in February 2015 provided for the demerger and hiving off of the consumer products business of Crompton Greaves on a going concern basis and its transfer to and vesting into Crompton Greaves Consumer Electricals.
    Trading/ Investment Ideas
Technical Calls
Company
Name
Recommendation CMP Initiation
Range
Stop
loss
Target Time
Frame
HEXAWARE BUY 260.95 255-258 248 278 3-5 Days
BAJAJ-AUTO SELL MAR FUT 2238.00 2245-2260 2305 2100 3-5 Days
 
Derivatives Call
Company
Name
Recommendation CMP Initiation
Price
Stop
loss
Target Time
Frame
AMBUJACEM BUY MAR FUTS 205.70 203-204 196 216 3-5 Days
 
Fundamental Picks for delivery (9 Months - 1 Year)
Company
Name
Recommendation CMP Initiation
Range
Target
SMLISUZU BUY 765.15 869.00 1150
JYOTHYLAB BUY 284.25 272.40 330
SUPREMEIND BUY 774.05 699.30 840
Note – For our running recommendations and past performance, please click here
Research Disclaimer